



## **New York State Medicaid Drug Utilization Review Board Meeting Agenda**

The Drug Utilization Review (DUR) Board will meet on September 19, 2019, from 9:00 a.m. to 4:00 p.m., Meeting Room 3, Concourse, Empire State Plaza, Albany, New York

### **Agenda Items**

#### **A. Pharmacy Program Updates**

The DUR Board will be provided updates on the following topics:

1. Drug Cap Reporting pursuant to Public Health Law (PHL) §280.
2. Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act.  
<https://www.congress.gov/115/bills/hr6/BILLS-115hr6enr.pdf>

#### **B. Drug Utilization Reviews**

The DUR Board will review the following topics and, if applicable, recommend clinical criteria and/or interventions to ensure appropriate utilization:

1. Opioid utilization as related to the SUPPORT Act.
2. Antipsychotic utilization in children as related to the SUPPORT Act.
3. Opioid and Antipsychotic concurrent utilization as related to the SUPPORT Act.
4. Leukotriene Modifier utilization in the treatment of asthma.

#### **C. Clinical Editing Updates**

The DUR Board will be provided information associated with current clinical criteria and/or interventions for:

1. Utilization of antiretroviral combinations (for the treatment of HIV/AIDS) and associated drug interactions.

**Agenda Timeline** (subject to change based on meeting proceedings)

9:00 - 9:15	Welcome and Opening Comments
9:15 - 10:15	Public Comment Period
10:15 - 11:00	Pharmacy Program Updates
11:00 - 12:30	Drug Utilization Reviews
12:30 - 1:30	Lunch/Executive Session
1:30 - 2:30	Drug Utilization Reviews (cont.)
2:30 - 3:30	Clinical Editing Updates
3:30 - 4:00	Final Comments and Adjournment

Interested parties must submit a request to provide public comment during the DUR Board meeting and must complete the registration process by September 12, 2019. Requests to provide public comment may be made by calling 518-486-3209 or e-mailing [dur@health.ny.gov](mailto:dur@health.ny.gov). (please reference DUR Board Meeting speaker request).

Public comments are limited to items on the agenda. Comments must be brief (2 minutes) and the total comment period will not exceed sixty (60) minutes. DoH reserves the right to limit the number of interested parties providing public comment in order to meet meeting timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by September 12, 2019. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by September 5, 2019 or the DUR Board may not have ample time to review the information.

All information must be sent to the DoH. Interested parties should not contact or send any information directly to DUR Board members.